949902-88-9

Usage

Uses

Used in Pharmaceutical and Agrochemical Industries:
(2-hydroxyethyl)phenethylcarbamic acid t-butyl ester is used as a reactive intermediate for the synthesis of various pharmaceuticals and agrochemicals. Its stability and reactivity make it a valuable component in the development of new drugs and agricultural products.
Used in Organic Synthesis:
(2-hydroxyethyl)phenethylcarbamic acid t-butyl ester is used as a building block in organic synthesis for creating complex organic molecules. Its unique structure allows for versatile reactions and the formation of a wide range of compounds.
Used in Medicinal Chemistry:
(2-hydroxyethyl)phenethylcarbamic acid t-butyl ester is used as a starting material in medicinal chemistry for the design and synthesis of new therapeutic agents. Its reactivity and structural features can be exploited to create novel drug candidates with potential therapeutic benefits.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 2842-37-7 2-(phenethylamino)ethanol 
• 103-63-9 1-phenyl-2-bromoethane 
• 54608-35-4 N-phenethylglycine ethyl ester 
• 193818-10-9 (t-butoxycarbonylphenethylamino)acetic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 122-78-1 phenylacetaldehyde 

Downstream Products

• 1018909-36-8 C₁₅H₂₂N₄O₂ 
• 182921-00-2 (2-oxoethyl)phenethylcarbamic acid t-butyl ester 
• 145549-11-7 tert-butyl (R)-3-phenylpyrrolidine-1-carboxylate 

Relevant academic research and scientific papers

Discovery of Axelopran (TD-1211): A Peripherally Restricted μ-Opioid Receptor Antagonist

The effects of opioids in the central nervous system (CNS) provide significant benefit in the treatment of pain but can also lead to physical dependence and addiction, which has contributed to a growing opioid epidemic in the United States. Gastrointestinal dysfunction is an additional serious consequence of opioid use, and this can be treated with a localized drug distribution of a non-CNS penetrant, peripherally restricted opioid receptor antagonist. Herein, we describe the application of Theravance's multivalent approach to drug discovery coupled with a physicochemical property design strategy by which the N-substituted-endo-3-(8-aza-bicyclo[3.2.1]oct-3-yl)-phenyl carboxamide series of μ-opioid receptor antagonists was optimized to afford the orally absorbed, non-CNS penetrant, Phase 3 ready clinical compound axelopran (TD-1211) 19i as a potential treatment for opioid-induced constipation.

Enantioselective Radical Cyclization for Construction of 5-Membered Ring Structures by Metalloradical C-H Alkylation

Radical cyclization represents a powerful strategy for construction of ring structures. Traditional radical cyclization, which is based on radical addition as the key step, necessitates the use of unsaturated substrates. Guided by the concept of metalloradical catalysis, a different mode of radical cyclization that can employ saturated C-H substrates is demonstrated through the development of a Co(II)-based system for catalytic activation of aliphatic diazo compounds for enantioselective radical alkylation of various C(sp3)-H bonds. It allows for efficient construction of chiral pyrrolidines and other valuable 5-membered cyclic compounds. This alternative strategy of radical cyclization provides a new retrosynthetic paradigm to prepare five-membered cyclic molecules from readily available open-chain aldehydes through the union of C-H and C=O elements for C-C bond formation.

The discovery of new human coagulation factor XIa (FXIa) inhibitors by synthesis, biological evaluation, and structure-based modeling

Factor XIa (FXIa) is an enzyme that is activated during the earliest stage of initiation of the intrinsic pathway of the blood coagulation mechanism. In this study, we attempted to discover a new FXIa inhibitor based on structure-based molecular modeling. We found that compound 16 exhibits satisfactory predicted properties while maintaining important binding interactions with FX1a.

New Compound Having Inhibition Activity to Factor XIa

The present invention relates to a pharmacologically active amount of a novel compound, represented by chemical formula 1, having inhibition activity against factor XIa, a producing method thereof, and a pharmaceutical composition comprising: a pharmaceut

Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping

Selective inhibition of neuronal nitric oxide synthase (nNOS) has been shown to prevent brain injury and is important for the treatment of various neurodegenerative disorders. This study shows that not only greater inhibitory potency and isozyme selectivity but more druglike properties can be achieved by fragment hopping. On the basis of the structure of lead molecule 6, fragment hopping effectively extracted the minimal pharmacophoric elements in the active site of nNOS for ligand hydrophobic and steric interactions and generated appropriate lipophilic fragments for lead optimization. More potent and selective inhibitors with better druglike properties were obtained within the design of 20 derivatives (compounds 7-26). Our structure - based inhibitor design for nNOS and SAR analysis reveal the robustness and efficiency of fragment hopping in lead discovery and structural optimization, which implicates a broad application of this approach to many other therapeutic targets for which known druglike small-molecule modulators are still limited.

8-Azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists

The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, A, and G are defined in the specification, or a pharmaceutically-acceptable salt or solvate thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.